PIPELINE
By dedicating an independent company to each asset, Dauntless offers a faster and more capital efficient way to advance clinical candidates. Each company has the benefit of Dauntless’ expertise across the drug development continuum.
Asset Company | Pre-Clinical | Clinical Development | ||||
---|---|---|---|---|---|---|
Formulations | POC | Toxicology | Safety | Proof-of-Concept | Pivotal | |
DP2018
Octreotide Depot |
acromegaly/NETs
|
|||||
DP1038
DP1038 Intranasal Octreotide |
acromegaly / neuroendocrine tumors / CID
|
|||||
Dauntless 3
Coming Soon |
Asset Company | Phase |
---|---|
DP1038 DP1038 Intranasal Octreotide |
Proof-of-Concept |
DP2018 DP2018 Undisclosed Asset |
Pre-Clinical |
Dauntless 3 Coming Soon |